Previous 10 | Next 10 |
2024-06-13 14:00:08 ET Glen Santangelo from Jefferies issued a price target of $36.00 for PCRX on 2024-06-13 11:57:00. The adjusted price target was set to $36.00. At the time of the announcement, PCRX was trading at $28.5. The overall price target consensus is at $52.33...
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024 in New York. Live audio of the event can b...
2024-05-10 07:17:48 ET More on Pacira BioSciences Pacira Biosciences announces proposed offering of $250M aggregate principal amount of convertible senior notes Pacira BioSciences up 12% on stock buyback, Q1 top-line beat Read the full article on Seeking Alpha ...
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule...
2024-05-08 16:36:45 ET More on Pacira BioSciences Pacira BioSciences up 12% on stock buyback, Q1 top-line beat Pacira BioSciences GAAP EPS of $0.54 beats by $0.15, revenue of $181.2M beats by $0.34M Read the full article on Seeking Alpha For further details s...
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement...
2024-05-08 13:08:11 ET More on Pacira BioSciences Pacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript Pacira BioSciences, Inc. (PCRX) Q4 2023 Earnings Call Transcript Pacira ...
2024-05-07 21:14:02 ET Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Conference Call May 07, 2024, 04:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charles Reinhart - Chief Financial Officer Jona...
2024-05-07 17:29:16 ET More on Pacira BioSciences Pacira BioSciences, Inc. (PCRX) Q4 2023 Earnings Call Transcript Pacira BioSciences GAAP EPS of $0.54 beats by $0.15, revenue of $181.2M beats by $0.34M Pacira BioSciences Q4 2023 Earnings Preview Seeking Alph...
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...